AR095421A1 - Moduladores de p2x7 - Google Patents

Moduladores de p2x7

Info

Publication number
AR095421A1
AR095421A1 ARP140100965A ARP140100965A AR095421A1 AR 095421 A1 AR095421 A1 AR 095421A1 AR P140100965 A ARP140100965 A AR P140100965A AR P140100965 A ARP140100965 A AR P140100965A AR 095421 A1 AR095421 A1 AR 095421A1
Authority
AR
Argentina
Prior art keywords
pyridinyl
phenyl
pyrazizyl
thiophenyl
pyrazinyl
Prior art date
Application number
ARP140100965A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR095421A1 publication Critical patent/AR095421A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) o un enantiómero o diastereómero de este; o una sal farmacéuticamente aceptable de estos; en donde n es un entero de 0 - 1; X es CH₂ cuando n es 0, o X es CH₂ u oxígeno cuando n es 1; R¹ es fenilo o piridinilo, en donde el fenilo o piridinilo se sustituye, opcionalmente, con 1 a 4 sustituyentes seleccionados independientemente de halógeno y alquilo; y R² es fenilo, piridinilo, pirazinilo, piradizinilo, pirimidinilo, pirrolilo, pirazolilo, tiazolilo o tiofenilo, en donde el fenilo, piridinilo, pirazinilo, piradizinilo, pirimidinilo, pirrolilo, pirazolilo, tiazolilo o tiofenilo se sustituye, opcionalmente, con 1 a 2 sustituyentes seleccionados independientemente del grupo que consiste en halógeno, alquilo, hidroxi y alcoxi.
ARP140100965A 2013-03-14 2014-03-13 Moduladores de p2x7 AR095421A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785558P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
AR095421A1 true AR095421A1 (es) 2015-10-14

Family

ID=50631041

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100965A AR095421A1 (es) 2013-03-14 2014-03-13 Moduladores de p2x7

Country Status (10)

Country Link
US (3) US9540388B2 (es)
EP (2) EP3309161B1 (es)
JP (1) JP6294954B2 (es)
AR (1) AR095421A1 (es)
ES (2) ES2776654T3 (es)
HK (2) HK1218649A1 (es)
JO (1) JO3509B1 (es)
TW (1) TWI627174B (es)
UY (1) UY35447A (es)
WO (1) WO2014152621A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3509B1 (ar) * 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US9096596B2 (en) 2013-03-14 2015-08-04 Janssen Pharmaceutica Nv P2X7 modulators
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
JP6592510B2 (ja) * 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
AU2016252686B2 (en) 2015-04-24 2019-03-14 Shionogi & Co., Ltd. 6-membered heterocyclic derivative and pharmaceutical composition comprising same
WO2017040772A1 (en) * 2015-09-04 2017-03-09 Janssen Pharmaceutica Nv Therapeutic compounds and synthesis
CN105596301A (zh) * 2016-01-29 2016-05-25 中国药科大学 一种以异喹啉为基本骨架的p2x7受体拮抗剂的纳米混悬剂及其制备方法
CN105503884B (zh) * 2016-02-17 2017-10-13 上海皓元生物医药科技有限公司 一种用于合成bet蛋白抑制剂的关键中间体的合成方法
MX2019004107A (es) 2016-10-17 2019-08-05 Shionogi & Co Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene.
US20200102311A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP4038070A1 (en) 2019-09-30 2022-08-10 Janssen Pharmaceutica NV Radiolabelled mgl pet ligands
KR20220157999A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US905687A (en) 1908-07-14 1908-12-01 Samuel W Evans Jr Folding umbrella and cane.
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
JP3208139B2 (ja) 1990-10-02 2001-09-10 ワーナー−ランバート・コンパニー アンギオテンシン▲ｉｉ▼アンタゴニスト
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
US20060100233A1 (en) 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
AU2005277283A1 (en) 2004-08-23 2006-03-02 Merck Sharp & Dohme Corp. Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP2008528580A (ja) 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
BRPI0812909A2 (pt) 2007-06-21 2014-12-09 Schering Corp Derivados de guanina policíclica e métodos de uso dos mesmos.
CA2691512A1 (en) 2007-08-10 2009-02-19 H. Lundbeck A/S Heteroaryl amide analogues
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
CN102066360B (zh) 2008-04-22 2013-10-30 詹森药业有限公司 喹啉或异喹啉取代的p2x7拮抗剂
JP5063815B2 (ja) 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
US8501946B2 (en) * 2009-04-29 2013-08-06 Glaxo Group Limited 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
PL2552920T3 (pl) 2010-04-02 2017-08-31 Ogeda Sa Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3
WO2011128769A2 (en) 2010-04-16 2011-10-20 Rodrigo Graf Fernandez Foldable structures for a construction
WO2012040048A2 (en) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones as p2x7 receptor antagonists
MX2014014234A (es) 2012-05-22 2015-05-07 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
PE20150887A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
NZ706775A (en) 2012-10-16 2018-10-26 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
SG10201703533VA (en) 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
PL2935248T3 (pl) 2012-12-21 2018-07-31 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania dla nich
WO2014100818A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
UY35370A (es) 2013-03-06 2014-09-30 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4
US9096596B2 (en) 2013-03-14 2015-08-04 Janssen Pharmaceutica Nv P2X7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
TW201522307A (zh) 2013-03-14 2015-06-16 百靈佳殷格翰國際股份有限公司 經取代２－氮雜－雙環［２．２．１］庚烷－３－羧酸（苄基－氰基－甲基）－醯胺組織蛋白酶ｃ抑制劑
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
KR101780784B1 (ko) 2013-03-14 2017-09-21 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 2,3-이치환된 1-아실-4-아미노-1,2,3,4-테트라하이드로퀴놀린 유도체 및 이의 브로모도메인 억제제로서의 용도
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
AU2014265957A1 (en) 2013-03-14 2015-09-10 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
SG10201707545XA (en) 2013-03-14 2017-10-30 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9840508B2 (en) 2013-03-29 2017-12-12 Oged Sa N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
EA201790600A1 (ru) 2014-09-12 2017-07-31 Янссен Фармацевтика Нв Модулирующие p2x7 n-ацил-триазолопиразины
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子

Also Published As

Publication number Publication date
HK1218649A1 (zh) 2017-03-03
WO2014152621A1 (en) 2014-09-25
EP3309161A1 (en) 2018-04-18
JO3509B1 (ar) 2020-07-05
UY35447A (es) 2014-09-30
US20140275056A1 (en) 2014-09-18
HK1254111A1 (zh) 2019-07-12
JP6294954B2 (ja) 2018-03-14
ES2776654T3 (es) 2020-07-31
US10053462B2 (en) 2018-08-21
US20170088550A1 (en) 2017-03-30
JP2016513702A (ja) 2016-05-16
ES2652648T3 (es) 2018-02-05
US9102686B2 (en) 2015-08-11
TW201522339A (zh) 2015-06-16
EP2970287A1 (en) 2016-01-20
US20160039836A1 (en) 2016-02-11
EP2970287B1 (en) 2017-11-01
US9540388B2 (en) 2017-01-10
TWI627174B (zh) 2018-06-21
EP3309161B1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
AR095421A1 (es) Moduladores de p2x7
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR119761A2 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR095523A1 (es) Derivados piridin-4-ilo
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
TR201900050T4 (tr) Kaynaştırılmış heterosiklik bileşik ve bunun haşere kontrol uygulaması.
SA515361086B1 (ar) Fasn مركبات وتركيبات جديدة لتثبيط
ES2721031T3 (es) Compuestos de dihidroisoquinolinona sustituidos
RS54730B1 (sr) Inhibitori beta sekretaze
AR098522A1 (es) Compuesto de triazolo-piridina
RS54183B1 (en) PIRAZOLE DERIVATIVES
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
AR097866A1 (es) Derivados de 4-azaindol
AR107428A1 (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
AR091770A1 (es) Indolcarbonitrilos moduladores selectivos de receptores androgenicos
AR101132A1 (es) Derivados de pirazina agonistas del gpr40 para el tratamiento de la diabetes tipo ii
AR100439A1 (es) Derivados de carboxamida
AR095097A1 (es) Compuestos de fenoxietoxi
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
AR097253A1 (es) Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida
AR098965A1 (es) Derivados de sulfonamidas tricíclicas
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T

Legal Events

Date Code Title Description
FB Suspension of granting procedure